Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.02
ZMH's Cash to Debt is ranked lower than
64% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZMH: 1.02 )
Ranked among companies with meaningful Cash to Debt only.
ZMH' s 10-Year Cash to Debt Range
Min: 0.05  Med: 0.85 Max: N/A
Current: 1.02
Equity to Asset 0.38
ZMH's Equity to Asset is ranked lower than
81% of the 287 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. ZMH: 0.38 )
Ranked among companies with meaningful Equity to Asset only.
ZMH' s 10-Year Equity to Asset Range
Min: 0.03  Med: 0.68 Max: 0.84
Current: 0.38
0.03
0.84
Interest Coverage 0.88
ZMH's Interest Coverage is ranked lower than
98% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 10000.00 vs. ZMH: 0.88 )
Ranked among companies with meaningful Interest Coverage only.
ZMH' s 10-Year Interest Coverage Range
Min: 0.88  Med: 24.08 Max: 9999.99
Current: 0.88
0.88
9999.99
F-Score: 3
Z-Score: 3.00
WACC vs ROIC
11.12%
15.04%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 21.76
ZMH's Operating margin (%) is ranked higher than
92% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. ZMH: 21.76 )
Ranked among companies with meaningful Operating margin (%) only.
ZMH' s 10-Year Operating margin (%) Range
Min: 9.72  Med: 24.88 Max: 33.34
Current: 21.76
9.72
33.34
Net-margin (%) 14.54
ZMH's Net-margin (%) is ranked higher than
87% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.45 vs. ZMH: 14.54 )
Ranked among companies with meaningful Net-margin (%) only.
ZMH' s 10-Year Net-margin (%) Range
Min: 2.35  Med: 17.52 Max: 23.87
Current: 14.54
2.35
23.87
ROE (%) 12.95
ZMH's ROE (%) is ranked higher than
79% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ZMH: 12.95 )
Ranked among companies with meaningful ROE (%) only.
ZMH' s 10-Year ROE (%) Range
Min: 1.81  Med: 15.10 Max: 115.87
Current: 12.95
1.81
115.87
ROA (%) 7.32
ZMH's ROA (%) is ranked higher than
76% of the 324 Companies
in the Global Medical Devices industry.

( Industry Median: -0.62 vs. ZMH: 7.32 )
Ranked among companies with meaningful ROA (%) only.
ZMH' s 10-Year ROA (%) Range
Min: 0.78  Med: 10.75 Max: 32.15
Current: 7.32
0.78
32.15
ROC (Joel Greenblatt) (%) 40.90
ZMH's ROC (Joel Greenblatt) (%) is ranked higher than
86% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 3.55 vs. ZMH: 40.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZMH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 15.01  Med: 51.06 Max: 119.58
Current: 40.9
15.01
119.58
Revenue Growth (3Y)(%) -7.00
ZMH's Revenue Growth (3Y)(%) is ranked lower than
73% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. ZMH: -7.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZMH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7  Med: 10.55 Max: 25.6
Current: -7
-7
25.6
EBITDA Growth (3Y)(%) -13.30
ZMH's EBITDA Growth (3Y)(%) is ranked lower than
68% of the 171 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. ZMH: -13.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ZMH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -13.3  Med: 9.15 Max: 39.6
Current: -13.3
-13.3
39.6
EPS Growth (3Y)(%) -51.80
ZMH's EPS Growth (3Y)(%) is ranked lower than
94% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: -2.00 vs. ZMH: -51.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ZMH' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.8  Med: 11.55 Max: 41.7
Current: -51.8
-51.8
41.7
» ZMH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ZMH Guru Trades in Q2 2014

Andreas Halvorsen 603,193 sh (New)
Jim Simons 760,200 sh (+113.68%)
Robert Olstein 87,000 sh (+29.85%)
David Dreman 1,666 sh (+8.82%)
RS Investment Management 63,250 sh (+0.24%)
Steven Cohen 378,709 sh (unchged)
Scott Black Sold Out
Mario Gabelli 308,121 sh (-0.09%)
Ken Fisher 170,061 sh (-0.88%)
PRIMECAP Management 450,100 sh (-1.55%)
Jeff Auxier 93,417 sh (-2.21%)
Private Capital 151,365 sh (-3.13%)
Bill Frels 637,320 sh (-3.58%)
HOTCHKIS & WILEY 1,536,345 sh (-3.94%)
Paul Tudor Jones 12,470 sh (-10.15%)
Pioneer Investments 295,991 sh (-15.11%)
Vanguard Health Care Fund 1,779,800 sh (-17.07%)
John Rogers 753,063 sh (-20.94%)
First Eagle Investment 1,122 sh (-31.25%)
Jeremy Grantham 1,054,694 sh (-39.13%)
Joel Greenblatt 4,631 sh (-89.84%)
» More
Q3 2014

ZMH Guru Trades in Q3 2014

Scott Black 86,763 sh (New)
Louis Moore Bacon 155,000 sh (New)
Paul Tudor Jones 412,347 sh (+3206.71%)
John Rogers 1,047,358 sh (+39.08%)
Robert Olstein 108,000 sh (+24.14%)
Jeremy Grantham 1,117,893 sh (+5.99%)
David Dreman 1,721 sh (+3.30%)
RS Investment Management 64,515 sh (+2.00%)
Mario Gabelli 313,486 sh (+1.74%)
Ken Fisher 170,119 sh (+0.03%)
Pioneer Investments 289,618 sh (unchged)
Andreas Halvorsen Sold Out
Jeff Auxier 93,267 sh (-0.16%)
PRIMECAP Management 449,204 sh (-0.20%)
Bill Frels 630,696 sh (-1.04%)
HOTCHKIS & WILEY 1,470,345 sh (-4.30%)
Joel Greenblatt 4,418 sh (-4.60%)
Private Capital 135,920 sh (-10.20%)
Vanguard Health Care Fund 1,589,200 sh (-10.71%)
First Eagle Investment 873 sh (-22.19%)
Steven Cohen 261,800 sh (-30.87%)
Jim Simons 387,600 sh (-49.01%)
» More
Q4 2014

ZMH Guru Trades in Q4 2014

Ray Dalio 2,028 sh (New)
First Eagle Investment 873 sh (unchged)
Vanguard Health Care Fund 1,589,200 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 289,174 sh (-0.15%)
Jeff Auxier 92,942 sh (-0.35%)
PRIMECAP Management 446,704 sh (-0.56%)
John Rogers 1,040,965 sh (-0.61%)
HOTCHKIS & WILEY 1,457,788 sh (-0.85%)
Private Capital 133,375 sh (-1.87%)
RS Investment Management 63,110 sh (-2.18%)
Mario Gabelli 304,667 sh (-2.81%)
Ken Fisher 164,121 sh (-3.53%)
Scott Black 81,302 sh (-6.29%)
Bill Frels 558,549 sh (-11.44%)
Steven Cohen 228,900 sh (-12.57%)
Jeremy Grantham 966,816 sh (-13.51%)
David Dreman 1,487 sh (-13.60%)
Joel Greenblatt 3,685 sh (-16.59%)
Robert Olstein 82,000 sh (-24.07%)
Jim Simons 182,200 sh (-52.99%)
Paul Tudor Jones 5,342 sh (-98.70%)
» More
Q1 2015

ZMH Guru Trades in Q1 2015

John Hussman 50,000 sh (New)
Eric Mindich 1,593,415 sh (New)
Paul Tudor Jones 167,318 sh (+3032.12%)
Jim Simons 327,300 sh (+79.64%)
PRIMECAP Management 544,304 sh (+21.85%)
Steven Cohen 276,900 sh (+20.97%)
Pioneer Investments 316,334 sh (+9.39%)
Ken Fisher 168,682 sh (+2.78%)
RS Investment Management 64,447 sh (+2.12%)
John Rogers 1,060,404 sh (+1.87%)
Jeremy Grantham 972,653 sh (+0.60%)
Vanguard Health Care Fund 1,589,200 sh (unchged)
First Eagle Investment 873 sh (unchged)
Joel Greenblatt Sold Out
Ray Dalio Sold Out
Mario Gabelli 302,867 sh (-0.59%)
Private Capital 131,810 sh (-1.17%)
Bill Frels 530,955 sh (-4.94%)
Scott Black 76,891 sh (-5.43%)
HOTCHKIS & WILEY 1,328,982 sh (-8.84%)
Robert Olstein 71,000 sh (-13.41%)
Jeff Auxier 42,364 sh (-54.42%)
David Dreman 280 sh (-81.17%)
» More
» Details

Insider Trades

Latest Guru Trades with ZMH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Zimmer Holdings Inc

Eric Mindich Increases His Most Valuable Stake in First Quarter
Eric Mindich (Trades, Portfolio), founder and CEO of hedge fund Eton Park Capital Management, has a history of early success. At the age of 27, he was the youngest partner in Goldman Sachs’ (GS) history. He left Goldman Sachs a decade later to start Eton Park – one of the largest fund launches in history at $3.5 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 29.00
ZMH's P/E(ttm) is ranked lower than
53% of the 155 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. ZMH: 29.00 )
Ranked among companies with meaningful P/E(ttm) only.
ZMH' s 10-Year P/E(ttm) Range
Min: 9.08  Med: 20.72 Max: 53.07
Current: 29
9.08
53.07
Forward P/E 14.77
ZMH's Forward P/E is ranked higher than
84% of the 97 Companies
in the Global Medical Devices industry.

( Industry Median: 22.68 vs. ZMH: 14.77 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.00
ZMH's PE(NRI) is ranked lower than
52% of the 153 Companies
in the Global Medical Devices industry.

( Industry Median: 28.20 vs. ZMH: 29.00 )
Ranked among companies with meaningful PE(NRI) only.
ZMH' s 10-Year PE(NRI) Range
Min: 9.07  Med: 20.73 Max: 53.03
Current: 29
9.07
53.03
P/B 2.94
ZMH's P/B is ranked higher than
55% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.23 vs. ZMH: 2.94 )
Ranked among companies with meaningful P/B only.
ZMH' s 10-Year P/B Range
Min: 1.31  Med: 2.52 Max: 5.52
Current: 2.94
1.31
5.52
P/S 4.20
ZMH's P/S is ranked lower than
60% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.28 vs. ZMH: 4.20 )
Ranked among companies with meaningful P/S only.
ZMH' s 10-Year P/S Range
Min: 1.82  Med: 3.49 Max: 7.26
Current: 4.2
1.82
7.26
PFCF 32.73
ZMH's PFCF is ranked lower than
52% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 32.21 vs. ZMH: 32.73 )
Ranked among companies with meaningful PFCF only.
ZMH' s 10-Year PFCF Range
Min: 9.54  Med: 21.05 Max: 36.62
Current: 32.73
9.54
36.62
POCF 20.39
ZMH's POCF is ranked higher than
56% of the 148 Companies
in the Global Medical Devices industry.

( Industry Median: 21.95 vs. ZMH: 20.39 )
Ranked among companies with meaningful POCF only.
ZMH' s 10-Year POCF Range
Min: 6.88  Med: 13.87 Max: 26.18
Current: 20.39
6.88
26.18
EV-to-EBIT 19.91
ZMH's EV-to-EBIT is ranked higher than
58% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 22.01 vs. ZMH: 19.91 )
Ranked among companies with meaningful EV-to-EBIT only.
ZMH' s 10-Year EV-to-EBIT Range
Min: 6.8  Med: 14.30 Max: 35.6
Current: 19.91
6.8
35.6
Shiller P/E 28.22
ZMH's Shiller P/E is ranked higher than
57% of the 95 Companies
in the Global Medical Devices industry.

( Industry Median: 31.07 vs. ZMH: 28.22 )
Ranked among companies with meaningful Shiller P/E only.
ZMH' s 10-Year Shiller P/E Range
Min: 10.67  Med: 19.13 Max: 38.89
Current: 28.22
10.67
38.89
Current Ratio 13.11
ZMH's Current Ratio is ranked higher than
96% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.53 vs. ZMH: 13.11 )
Ranked among companies with meaningful Current Ratio only.
ZMH' s 10-Year Current Ratio Range
Min: 1.14  Med: 2.94 Max: 13.11
Current: 13.11
1.14
13.11
Quick Ratio 11.78
ZMH's Quick Ratio is ranked higher than
96% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.00 vs. ZMH: 11.78 )
Ranked among companies with meaningful Quick Ratio only.
ZMH' s 10-Year Quick Ratio Range
Min: 0.71  Med: 1.87 Max: 11.78
Current: 11.78
0.71
11.78
Days Inventory 281.16
ZMH's Days Inventory is ranked lower than
80% of the 284 Companies
in the Global Medical Devices industry.

( Industry Median: 129.39 vs. ZMH: 281.16 )
Ranked among companies with meaningful Days Inventory only.
ZMH' s 10-Year Days Inventory Range
Min: 197.28  Med: 289.80 Max: 339.23
Current: 281.16
197.28
339.23
Days Sales Outstanding 68.33
ZMH's Days Sales Outstanding is ranked higher than
50% of the 276 Companies
in the Global Medical Devices industry.

( Industry Median: 68.45 vs. ZMH: 68.33 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZMH' s 10-Year Days Sales Outstanding Range
Min: 56.27  Med: 65.37 Max: 93.39
Current: 68.33
56.27
93.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.77
ZMH's Dividend Yield is ranked lower than
74% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 1.43 vs. ZMH: 0.77 )
Ranked among companies with meaningful Dividend Yield only.
ZMH' s 10-Year Dividend Yield Range
Min: 0.28  Med: 0.79 Max: 1.1
Current: 0.77
0.28
1.1
Dividend Payout 0.22
ZMH's Dividend Payout is ranked higher than
80% of the 108 Companies
in the Global Medical Devices industry.

( Industry Median: 0.41 vs. ZMH: 0.22 )
Ranked among companies with meaningful Dividend Payout only.
ZMH' s 10-Year Dividend Payout Range
Min: 0.15  Med: 0.21 Max: 0.24
Current: 0.22
0.15
0.24
Yield on cost (5-Year) 0.78
ZMH's Yield on cost (5-Year) is ranked lower than
72% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 1.37 vs. ZMH: 0.78 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ZMH' s 10-Year Yield on cost (5-Year) Range
Min: 0.28  Med: 0.80 Max: 1.1
Current: 0.78
0.28
1.1
Share Buyback Rate 100.00
ZMH's Share Buyback Rate is ranked higher than
99% of the 183 Companies
in the Global Medical Devices industry.

( Industry Median: -3.70 vs. ZMH: 100.00 )
Ranked among companies with meaningful Share Buyback Rate only.
ZMH' s 10-Year Share Buyback Rate Range
Min: 100  Med: 3.60 Max: -8.4
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 14.78
ZMH's Price/Net Current Asset Value is ranked lower than
78% of the 205 Companies
in the Global Medical Devices industry.

( Industry Median: 6.76 vs. ZMH: 14.78 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZMH' s 10-Year Price/Net Current Asset Value Range
Min: 12.23  Med: 20.01 Max: 486.31
Current: 14.78
12.23
486.31
Price/Tangible Book 5.40
ZMH's Price/Tangible Book is ranked lower than
56% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 4.56 vs. ZMH: 5.40 )
Ranked among companies with meaningful Price/Tangible Book only.
ZMH' s 10-Year Price/Tangible Book Range
Min: 4.19  Med: 7.44 Max: 233.33
Current: 5.4
4.19
233.33
Price/Projected FCF 1.49
ZMH's Price/Projected FCF is ranked higher than
70% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 1.95 vs. ZMH: 1.49 )
Ranked among companies with meaningful Price/Projected FCF only.
ZMH' s 10-Year Price/Projected FCF Range
Min: 0.58  Med: 0.89 Max: 2.31
Current: 1.49
0.58
2.31
Price/Median PS Value 1.18
ZMH's Price/Median PS Value is ranked lower than
52% of the 264 Companies
in the Global Medical Devices industry.

( Industry Median: 1.16 vs. ZMH: 1.18 )
Ranked among companies with meaningful Price/Median PS Value only.
ZMH' s 10-Year Price/Median PS Value Range
Min: 0.57  Med: 1.33 Max: 2.62
Current: 1.18
0.57
2.62
Price/Graham Number 2.62
ZMH's Price/Graham Number is ranked lower than
53% of the 138 Companies
in the Global Medical Devices industry.

( Industry Median: 2.43 vs. ZMH: 2.62 )
Ranked among companies with meaningful Price/Graham Number only.
ZMH' s 10-Year Price/Graham Number Range
Min: 1.36  Med: 2.60 Max: 22.07
Current: 2.62
1.36
22.07
Earnings Yield (Greenblatt) (%) 5.00
ZMH's Earnings Yield (Greenblatt) (%) is ranked higher than
79% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 0.20 vs. ZMH: 5.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZMH' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.8  Med: 7.00 Max: 14.7
Current: 5
2.8
14.7
Forward Rate of Return (Yacktman) (%) 4.34
ZMH's Forward Rate of Return (Yacktman) (%) is ranked higher than
52% of the 98 Companies
in the Global Medical Devices industry.

( Industry Median: 4.08 vs. ZMH: 4.34 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ZMH' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 4.2  Med: 12.40 Max: 45.7
Current: 4.34
4.2
45.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, STJ, EW » details
Traded in other countries:ZIM.Germany, 0QQD.UK, ZBH.Switzerland,
Zimmer Holdings Inc was incorporated in 2001. The Company designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products. It also provides other healthcare related services. Its products include orthopaedic reconstructive implants, spinal and trauma devices, biologics, dental implants and related surgical products. Its orthopaedic reconstructive devices restore function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Its dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Its spinal devices are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Its trauma products are devices used to reattach or stabilize damaged bone and tissue to support the body's natural healing process. The Company has its operations in more than 25 countries and markets its products in more than 100 countries. The Company operates in a single industry but have three reportable geographic segments, the Americas, Europe and Asia Pacific. The Americas, which is comprised of the U.S. and includes other North, Central and South American markets; Europe, which is comprised of Europe and includes the Middle East and African markets; and Asia Pacific, which is comprised of Japan and includes other Asian and Pacific markets. The Company's customers include orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. It markets and sells its products through three channels; direct to healthcare institutions, such as hospitals, referred to as direct channel accounts; through stocking distributors and healthcare dealers; and directly to dental practices and dental laboratories. The Company operates distribution facilities domestically in Warsaw, Indiana; Southaven, Mississippi; and Carlsbad, California and internationally in Australia, Austria, Belgium, Canada, the Czech Republic, China, Finland, France, Germany, Hong Kong, India, Italy, Japan, Korea, Malaysia, the Netherlands, New Zealand, Portugal, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand and the United Kingdom. The Company competes with the DePuy Synthes Companies of Johnson & Johnson, Stryker Corporation, Biomet, Inc., and Smith & Nephew plc. It protects its proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information. The Company is subject to government regulation in the countries in which it conducts business.
» More Articles for ZMH

Headlines

Articles On GuruFocus.com
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015 
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Weekly 52-Week Highs Highlight: TGT, THI, TRI, ZMH Nov 17 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Simon Properties Reports Insider Trades Mar 13 2013 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
These 5 Stocks Are Most Hated by Big Investors Nov 07 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 

More From Other Websites
Zimmer-Biomet Merger Completes, 2015 Guidance Updated - Analyst Blog Jun 29 2015
ZIMMER BIOMET HOLDINGS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets,... Jun 26 2015
Brean Capital Cashes Out Of Zimmer Holdings, Downgrades Stock On 'Uncertainty' Jun 25 2015
Zimmer Hldgs downgraded by Brean Capital Jun 25 2015
Biomet, Inc. -- Moody's downgrades Zimmer's ratings to Baa3 from Baa1; outlook stable Jun 24 2015
Zimmer buys Biomet in $14 bln deal, to divest some assets Jun 24 2015
Zimmer buys Biomet in $14 bln deal, to divest some assets Jun 24 2015
Orthopedic device makers Zimmer, Biomet say they've combined Jun 24 2015
Orthopedic device makers Zimmer, Biomet say they've combined Jun 24 2015
Medical device makers Zimmer and Biomet say they've combined Jun 24 2015
Medical device makers Zimmer and Biomet say they've combined Jun 24 2015
Medical-Device Maker Zimmer Narrows Revenue Projection Jun 24 2015
Jun 24, 2015 Zimmer Completes Combination with Biomet Jun 24 2015
Zimmer Completes Combination with Biomet Jun 24 2015
Zimmer to divest assets to win U.S. permission buy Biomet Jun 24 2015
Eric Mindich Increases His Most Valuable Stake in First Quarter Jun 12 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 29 2015
May 28, 2015 Zimmer Announces Agreements in Furtherance of Pending Biomet Merger May 28 2015
Zimmer Announces Agreements in Furtherance of Pending Biomet Merger May 28 2015
ZIMMER HOLDINGS INC Financials May 13 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK